Cms sepsis core measure set 2017

Size: px
Start display at page:

Download "Cms sepsis core measure set 2017"

Transcription

1 content=" Cms sepsis core measure set 2017 Testing for acute Hepatitis A (IgM HAV) should occur in patients presenting with acute hepatitis and possible fecal-oral exposure. Testing for acute hepatitis E (IgM HEV) should also be considered in those returning from endemic areas and whose tests for acute hepatitis A, B, and C are negative. (Strong recommendation, very low level of evidence). Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition,. Before initiation of evaluation of abnormal liver chemistries, one should repeat the lab panel and/or perform a clarifying test (e.g., GGT if serum alkaline phosphate is elevated) to confirm that the liver chemistry is actually abnormal. (Strong recommendation, very low level of evidence). Entrustable Professional Activities (EPAs) for GI Fellowship Training. Testing for chronic hepatitis B is conducted with HBsAg testing. Testing for acute hepatitis B is with HBsAg and IgM anti-hbc. The following groups are at highest risk: persons born in endemic or hyperendemic areas (HBsAg prevalence >2%), men who have sex with men, persons who have ever

2 used injection drugs, dialysis patients, HIV-infected individuals, pregnant women, and family members, household members, and sexual contacts of HBV-infected persons. (Strong recommendation, very low level of evidence). Testing for chronic hepatitis C is conducted with anti-hcv and confirmation is performed with HCV-RNA by nucleic acid testing. Risk factors for hepatitis C include history of intranasal or intravenous drug use, tattoos, body piercings, blood transfusions, high risk sexual conduct, and those born between 1945 and Testing for acute hepatitis C is with anti-hcv and HCV RNA by nucleic acid testing. (Strong recommendation, very low level of evidence). Albumin, bilirubin, and prothrombin time are markers of hepatocellular function that can be influenced by extrahepatic factors. An elevated alkaline phosphatase level of hepatic origin may be confirmed by elevation of gamma-glutamyl transferase (GGT) or fractionation of alkaline phosphatase. Policies and Procedures for Identifying and Resolving Conflicts of Interest. Patients with elevated BMI and other features of metabolic syndrome including diabetes mellitus, overweight or obesity, hyperlipidemia, or hypertension with mild elevations of ALT should undergo screening for NAFLD with ultrasound. (Strong recommendation, very low level of evidence). Paul Y. Kwo, MD, FACG, FAASLD 1, Stanley M. Cohen, MD, FACG, FAASLD 2 and Joseph K. Lim, MD, FACG, FAASLD 3. Received 11 February 2016; accepted 15 September Liver chemistries that are commonly ordered in comprehensive metabolic profiles are indirect markers of hepatobiliary disease. They are not true measures of hepatic function and thus are best referred to as liver chemistries or liver tests, and should not be referred to as liver function tests. True tests of liver function are not commonly performed but include measurement of hepatic substrates that are cleared by hepatic uptake, metabolism, or both processes (2). Because of the widespread use of the comprehensive metabolic profile testing that is done in routine practice to screen those who present for routine evaluation as well as those who are symptomatic and/or referred for elevation of abnormal liver chemistries, such abnormalities require a rational approach to interpretation. To date, there are no controlled trials that have been performed to determine the optimal approach to evaluate abnormal liver chemistries. This guideline has been developed to assist gastroenterologists and primary care providers in the interpretation of normal and abnormal liver chemistries as well as an approach to prioritize and evaluate those who present with abnormal liver chemistries. More than 14,000 GI professionals worldwide call themselves an ACG Member. Join the community of clinical gastroenterologists committed to providing quality in patient care. Members access a wide variety of resources and benefit from ACG's ongoing educational and legislative initiatives to ensure quality in care. ACG Home / Guideline / Evaluation of Abnormal Liver Chemistries. Please call the Communications Team at or . Patients with abnormal AST and ALT levels, particularly patients with other autoimmune conditions, should undergo testing for autoimmune liver disease including ANA, ASMA, and globulin level. (Strong recommendation, very low level of evidence). Journalists access information on digestive health, including the latest ACG news and up-to-date information about

3 ACG's Annual Scientific Meeting and the latest clinical science. Latest Findings from The American Journal of Gastroenterology. Am J Gastroenterol 2017;112:18-35; doi: /ajg ; published online 20 December Applying to GI Fellowship Programs: What You Need to Know. Authored by a talented group of GI experts, the College is devoted to the development of new ACG guidelines on gastrointestinal and liver diseases. Our guidelines reflect the current state-of-the-art scientific work and are based on the principles of evidence-based medicine. Dr. Dorrah is co-chair of the sepsis floor workgroup, which was charged with crafting one process that all seven hospitals in her system can follow to treat patients who develop sepsis on the floor. Rolled out this fall, the initiative includes a combination of nursing and provider education, nursing protocols, alerts in the Epic EHR and standard template documentation. In any given week that he works the hospitalist service, Dr. Odden in St. Louis may see no sepsis or severe sepsis cases, or he may see five or six. COMPLICATING MATTERS for hospitalists trying to deliver the new sepsis treatment bundle is the fact that groups of sepsis experts are publicly fighting over how to define sepsis. In its Feb. 23, 2016, issue, just four months after hospitals began reporting compliance with the sepsis bundle to the CMS, the Journal of the American Medical Association published an international consensus statement redefining sepsis and septic shock. Deborah Gesensway is a freelance writer who covers U.S. health care from Toronto. "Our average antibiotics time was four hours the last time we looked," Dr. Simpson says. That's due to delays in recognizing sepsis, in ordering tests and drugs, in pharmacy procedures, in transporting the medications from the pharmacy to the floor, in nurses realizing the meds are available, and, finally, in nurses administering the dose to the patient. Last year, the agency adopted a bundle of sepsis interventions as a core measure in its inpatient quality reporting program. As a result, hospitalists say, the challenges of treating sepsis have become much tougher. Part of Dr. Simpson's solution is outreach throughout Kansas, educating clinicians in hospitals state-wide about sepsis to help them get a jump on the diagnosis. According to Andrew Young, DO, the service chief of medicine at LAC+USC Medical Center and a co-author of that study, more recent preliminary data from his hospital show a 23% compliance rate with the CMS sepsis bundle. "The most challenging bundle elements to accomplish seem to be the repeat lactate, documenting the fluid infusion rate and having a stop time for the infusion.". For Dr. LaRosa in Newark, consistent bundle documentation can be frustrating. That's because the required focused exam within six hours of the Code SMART call is highly specific as to what elements must be contained in the note and, of course, in the patient evaluation to meet the standard. The CMS began requiring hospitals to submit sepsis-related data in October Eventually, those data may be publicly reported and affect hospital reimbursement. As for problems with documentation, "we are used to writing '2 liters IV bolus,' but our abstractors are saying that doesn't meet the core measure," Dr. Young explains. "Either the nurse needs to document when the bolus is done or we need to put in the infusion rate. We need to figure out how to tackle that.". "Unlike in an emergency department or an ICU, where you see a lot of

4 severe sepsis, you don't see it frequently on the med-surg units," Cooper's Dr. Dellinger points out. "On the floors, you have to train a lot of people and keep them poised for something that doesn't happen frequently.". As for why, the study noted that clinicians have fewer "distractions" at night and on weekends, allowing them to "focus on meeting the parameters necessary." (A study. abstract was presented at SHM's 2016 annual meeting.) Interestingly, the study also found that an increased rate of bundle compliance didn't boost patients' rate of survival to discharge. "There are a lot of advantages to nurse-based screening because it's a moment when someone is looking at all the information, even if it is very quickly," says Dr. Odden in St. Louis. The aim of screening is in part to "prompt a conversation with the physician. The secret ingredient is engaging both the nurses and physicians to try to put this together.". "It's definitely the hardest core measure I've ever tried to meet.". At Baylor Scott & White in Round Rock, this year's SepsisPalooza led to the formation of various workgroups to address specific bundle items. "It's definitely the hardest core measure I've ever tried to meet because it has a lot of components, and you have only three or six hours to complete them," Dr. Dorrah says. "As physicians, we often don't realize that 'Time Zero' has even been met because we're so busy trying to take care of the patient, not watch the clock.". Published in the December 2016 issue of Today's Hospitalist. The CMS bundle, which reflects Surviving Sepsis Campaign recommendations, requires hospitals to complete several interventions within three hours of a patient presenting with sepsis, then several more within six hours. (See " What's in the CMS sepsis bundle?") To get credit for meeting the measure, hospitals must achieve 100% compliance with all bundle elements, an "all-or-nothing" requirement that many hospitals struggle with. Some clinicians also either disagree with or are leery of some bundle elements, such as the call for large fluid boluses for nearly all patients with severe sepsis, even those with heart failure or end-stage renal disease. And even when people stay current, they may not be able to meet the measure, given the complicated institutions they work in. caring for patients with severe sepsis on the floor has always been a challenge. But now, the Centers for Medicare and Medicaid Services (CMS) has upped that ante. Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, understand the reasons behind lack of compliance with guidelines and to develop strategies. In addition to states that accept ANCC, NetCE is approved as a provider of continuing education in nursing by:. be prevented by minimal infection control efforts and 32% by "well organized and highly. Discuss the standards of professional conduct associated with infection control in the healthcare setting. Outline the infectious disease process. Describe various practices that can result in exposure to bloodborne pathogens. Identify effective strategies to prevent or control infection, including precautions, isolation techniques, hand hygiene, standards for cleaning, and safe injection practices. Describe the role of surveillance and reporting in an effective infection control program. Discuss the impact of communicable diseases in healthcare professionals, including the necessity for preplacement evaluations, periodic health assessments, education, and postexposure prophylaxis. Evaluate the impact and

5 appropriate response to sepsis. hospital costs related to three categories of HAIs it considers "reasonably preventable:". were the cause of approximately 75,000 deaths and add approximately $28.4 to $33.8 billion in. has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned. CSS 2.0 may work, but are not supported. Supported browsers must utilize the TLS encryption. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Completion of this course constitutes permission to share the completion data with ACCME. direct medical costs annually [4, 5, 95]. The most common types of HAIs were pneumonia (22%), surgical site. previously been estimated at a high of 1 in 10 [1, 4, 94, 95]. There were an estimated 722,000 HAIs in 648,000 adults and TEENren in. Your date of completion will be the date (Pacific Time) the course was electronically. Pass the mandatory test and/or evaluation and receive immediate feedback. Review the course material online or in print. (CDC) Study of Efficacy of Nosocomial Infection Control suggested that 6% of all HAIs could. pneumonia and K. oxytoca (10%), and Escherichia coli (9.5%). As HAIs have become a cause for increasing concern, many national organizations, state departments of health, and professional organizations have taken additional steps to prevent or control infection in the healthcare environment. that target those reasons. In addition, there are professional conseq averaged only 30% to 50% [3, 31, 44, 56, 57, 58]. Decreasing the number of HAIs will require research to better. In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Paul Y. Kwo, MD, FACG, FAASLD 1, Stanley M. Cohen, MD, FACG, FAASLD 2, and Joseph K. Lim, MD, FACG, FAASLD 3 1 Division of Gastroenterology/Hepatology,

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Approach to the Patient with Liver Disease

Approach to the Patient with Liver Disease Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases

More information

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose

More information

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary

More information

Disclosure. Evaluation of Abnormal Hepatic Enzymes

Disclosure. Evaluation of Abnormal Hepatic Enzymes Evaluation of Abnormal Hepatic Enzymes Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic Sayre, Pa Disclosure

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised

More information

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ

More information

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION

More information

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes

More information

DEPARTMENT: Regulatory Compliance Support

DEPARTMENT: Regulatory Compliance Support PAGE: 1 of 5 REPLACES POLICY DATED: 1/16/98, 3/1/99, SCOPE: All Company-affiliated hospitals performing and/or billing laboratory services. Specifically, the following departments: Business Office Admitting/Registration

More information

A Rational Evidence-based Approach to Abnormal Liver Tests

A Rational Evidence-based Approach to Abnormal Liver Tests A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does

More information

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries 18 PRACTICE GUIDELINES CME ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Paul Y. Kwo, MD, FACG, FAASLD 1, Stanley M. Cohen, MD, FACG, FAASLD 2 and Joseph K. Lim, MD, FACG, FAASLD 3 Clinicians

More information

Hepatitis Case Investigation

Hepatitis Case Investigation * indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS APPROACH TO THE PATIENT WITH ABNORMAL TESTS Kimberly A. Brown, M.D, FAST, FAASLD, AGAF Chief, Division of Gastroenterology and Hepatology Henry Ford Hospital Henry Ford Health System Detroit, Michigan

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis

More information

Monitoring Hepatitis C

Monitoring Hepatitis C Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody

More information

Hepatitis C January 26, 2018

Hepatitis C January 26, 2018 Hepatitis C January 26, 2018 Case Investigation Guidelines Contents A. Purpose...2 B. Case Definitions...2 a. Acute Hepatitis C (2016...2 b. Chronic Hepatitis C (2016)...3 c. Perinatal Hepatitis C (2017

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver

More information

Interpreting Liver Function Tests

Interpreting Liver Function Tests PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer

More information

Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider

Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider David Wolf, MD, FACP, FACG, AGAF, FAASLD Medical Director of Liver Transplantation Westchester Medical Center Professor of

More information

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver?

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver? EVALUATION & LISTING Your Child s Liver Transplant Evaluation The University of Michigan is a national leader in liver transplantation, as well as the surgical and medical management of patients with liver

More information

PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GYNECOLOGY/INFECTIOUS DISEASE. Scottsdale, Arizona The Phoenician February 8 10, 2019

PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GYNECOLOGY/INFECTIOUS DISEASE. Scottsdale, Arizona The Phoenician February 8 10, 2019 PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GYNECOLOGY/INFECTIOUS DISEASE Scottsdale, Arizona The Phoenician February 8 10, 2019 Friday, February 8th: 7:00 am 7:30 am Registration and

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical Investigations in Liver Disease Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical markers Albumin ALP ALT, AST Gamma-glutamyl transpeptidase

More information

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum

More information

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob: Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).

More information

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness

More information

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments

More information

Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD

Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD The assessment of patients with abnormal liver tests is common in both primary care and gastroenterology clinics. However, among patients

More information

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019 LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant

More information

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,

More information

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening

More information

Inpatient Quality Reporting Program

Inpatient Quality Reporting Program SEP-1 Early Management Bundle, Severe Sepsis/Septic Shock Part II Questions and Answers Moderator: Candace Jackson, RN Inpatient Quality Reporting (IQR) Program Lead Hospital Inpatient Value, Incentives,

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

Liver Function Testing. in primary care. Quiz Feedback

Liver Function Testing. in primary care. Quiz Feedback Liver Function Testing in primary care Quiz Feedback Contents Expert Summary, Associate Professor Ed Gane 3 Liver Function Testing in Primary Care Quiz 4 Quiz Feedback: Responses from Colleagues, and Specialist

More information

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional

More information

Hepatitis C Best Practice Guidelines For Local Health Departments

Hepatitis C Best Practice Guidelines For Local Health Departments Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Hepatitis A Virus: Old Things Made New

Hepatitis A Virus: Old Things Made New Hepatitis A Virus: Old Things Made New Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.A.Chastain@VUMC.org

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology

More information

Liver care in HIV Abnormal LFT s management

Liver care in HIV Abnormal LFT s management 14TH INTERNATIONAL WORKSHOP ON CO-INFECTION - HIV, Hepatitis & Liver Disease PRE-WORKSHOP EDUCATIONAL COURSE Liver care in HIV Abnormal LFT s management Juan Berenguer Hospital General Universitario Gregorio

More information

Hepatitis C Pre-Treatment Assessment

Hepatitis C Pre-Treatment Assessment Hepatitis C Pre-Treatment Assessment David C. Wolf, MD, FACP, FACG, AGAF, FAASLD Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College

More information

NYSDOH Sepsis Q&A Session from February 2018 Data Abstraction Meetings Table of Content

NYSDOH Sepsis Q&A Session from February 2018 Data Abstraction Meetings Table of Content NYSDOH Sepsis Q&A Session from February 2018 Data Abstraction Meetings Table of Content Adherence variables Q: within 3 hours of the start datetime. How can we document that monotherapy was started before

More information

Ocaliva (obeticholic acid tablets)

Ocaliva (obeticholic acid tablets) Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

To provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.

To provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids. TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider

Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider David C. Wolf, MD, FACP, FACG, AGAF, FAASLD Medical Director of Liver Transplantation Westchester Medical Center Professor

More information

5th Annual Post DDW Highlights Course

5th Annual Post DDW Highlights Course Northern California Society of Clinical Gastroenterology Cordially Invites you to a CME Symposium 5th Annual Post DDW Highlights Course Saturday, June 21, 2008 St. Regis Hotel San Francisco 125 Third Street

More information

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Management of Patients with Chronic Hepatitis B: The Alaska Experience Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts

More information

Session 11: The ABCs of LFTs Learning Objectives

Session 11: The ABCs of LFTs Learning Objectives Session 11: The ABCs of LFTs Learning Objectives 1. Define 3 key components of the patient history that should be further evaluated when liver function testing reveals elevated aminotransferases. 2. Identify

More information

Liver Disease. By: Michael Martins

Liver Disease. By: Michael Martins Liver Disease By: Michael Martins Recently I have been getting a flurry of patients that have some serious liver complications. This week s literature review will be the dental management of the patients

More information

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Investigating and Referring Incidental Findings of Abnormal Liver Tests Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common

More information

School Nursing and Health. Standard Precautions. (aka Universal Precautions)

School Nursing and Health. Standard Precautions. (aka Universal Precautions) School Nursing and Health Standard Precautions (aka Universal Precautions) August 2016 1 Standard Precautions Occupational Safety and Health Administration Federal Law 29 CFR bloodborne Pathogens 1910.1030(g)(2)(i)

More information

1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?

1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing? Drug Induced Liver Injury Cases Case #1 A.S., a16 year-old female, was found by her pediatrician to be slightly jaundiced during a routine school physical. She denied any history of liver disease, abdominal

More information

Hepatitis B at a Glance

Hepatitis B at a Glance Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if

More information

Immunization Update 2018

Immunization Update 2018 Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts

More information

What are LFTs? What are LFTs? 3/20/2017. Evaluation of Abnormal Liver Chemistry Tests. Transaminases. Alkaline phosphatase.

What are LFTs? What are LFTs? 3/20/2017. Evaluation of Abnormal Liver Chemistry Tests. Transaminases. Alkaline phosphatase. Evaluation of Abnormal Liver Chemistry Tests James Panetta, DO What are LFTs? Transaminases Alkaline phosphatase Bilirubin Gamma-glutamyl transpeptidase What are LFTs? 5 nucleosidase Lactate Dehydrogenase

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Scott W. Biggins, MD, MAS Assistant Professor Division of Gastroenterology UCSF Scott.Biggins@ucsf.edu (Thanks to Hal Yee, MD) This Morning s Presentation Clinical vignettes

More information

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis

More information

[Submitted Electronically]

[Submitted Electronically] [Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Strategy,, policy and commissioning on hepatitis B and C testing NICE Pathways bring together everything NICE says on a topic in an interactive flowchart. NICE Pathways are interactive and designed to

More information

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014 Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV

More information

Viral Hepatitis. Background

Viral Hepatitis. Background Viral Hepatitis Background Hepatitis or inflammation of the liver can be caused by infectious and noninfectious problems. Infectious etiologies include viruses, bacteria, fungi and parasites. Noninfectious

More information

@PremierHA #AdvisorLive. Download today s slides at

@PremierHA #AdvisorLive. Download today s slides at @PremierHA #AdvisorLive Download today s slides at www.premierinc.com/events Logistics Audio Use your computer speakers or dial in with the number on your screen Notes Download today s slides from the

More information

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic

More information

Management of Hepatitis B - Information for primary care providers

Management of Hepatitis B - Information for primary care providers Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines

More information

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses. Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

Pathophysiology I Liver and Biliary Disease

Pathophysiology I Liver and Biliary Disease Pathophysiology I Liver and Biliary Disease The Liver The liver is located in the right upper portion of the abdominal cavity just beneath the right side of the rib cage. The liver has many functions that

More information

BC Enhanced Hepatitis Strain Surveillance Project Hepatitis B. Acute HBV Questionnaire

BC Enhanced Hepatitis Strain Surveillance Project Hepatitis B. Acute HBV Questionnaire BC Enhanced Hepatitis Strain Surveillance Project Hepatitis B Informed Consent: Please read to individual and answer any questions There are about 60,000 people with hepatitis B in BC. We want to find

More information

Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy. Pharmacists Role 1

Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy. Pharmacists Role 1 Pharmacy 445 Public Health Applications in Pharmacy Jacqueline Gardner, Ph.D. Professor, Department of Pharmacy Pharmacists Role 1 Promotion of health improvement, wellness, and disease prevention in cooperation

More information

Hepatitis B and C Overview, Outbreaks, and Recommendations. Viral Hepatitis Language. Types of Viral Hepatitis 7/1/2013

Hepatitis B and C Overview, Outbreaks, and Recommendations. Viral Hepatitis Language. Types of Viral Hepatitis 7/1/2013 Hepatitis B and C Overview, Outbreaks, and Recommendations Elizabeth Lawlor, MS Healthy Kansans living in safe and sustainable environments. Viral Hepatitis Language Acute infection is when the infection

More information

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC : An Approach to Infectious and Other Causes Mary Anne Cooper MSc, MD, MEd, FRCPC Faculty: Dr. Mary Anne Cooper Relationships with commercial interests: Consulting Fees: Lupin Pharmaceuticals, Canada Objectives

More information

FRIDAY, MARCH 9 SUNDAY, MARCH

FRIDAY, MARCH 9 SUNDAY, MARCH 33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course

More information

LIVER DISEASE WRAP-UP

LIVER DISEASE WRAP-UP 20th Annual LIVER DISEASE WRAP-UP An Update on Advances in Clinical Hepatology An update on advances in clinical hepatology presented at the 2017 AASLD Meeting for Practicing Internists, Gastroenterologists,

More information

Sepsis 3.0: The Impact on Quality Improvement Programs

Sepsis 3.0: The Impact on Quality Improvement Programs Sepsis 3.0: The Impact on Quality Improvement Programs Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School of Brown University

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

Laboratory evaluation of the patient with liver disease

Laboratory evaluation of the patient with liver disease European Review for Medical and Pharmacological Sciences Laboratory evaluation of the patient with liver disease 2004; 8: 3-9 M. ASTEGIANO, N. SAPONE, B. DEMARCHI, S. ROSSETTI, R. BONARDI, M. RIZZETTO

More information

Sepsis Update: Early Identification and Management

Sepsis Update: Early Identification and Management Sepsis Update: Early Identification and Management Q&A From the Live Webinar Presenter: Tom Ahrens, RN, PhD, FAAN Live webinar: Thursday, May 09, 2013 The AACN Critical Care Webinar Series is not only

More information

Sepsis Early Recognition and Management. Therese Hughes, PhD, MPA, RN

Sepsis Early Recognition and Management. Therese Hughes, PhD, MPA, RN Sepsis Early Recognition and Management Therese Hughes, PhD, MPA, RN 1 Sepsis a Deadly Progression Affects millions around the world each year, killing one in four Contributes to approximately 50% of all

More information

Hepatitis C: Surveillance, Case Definition, and Investigation

Hepatitis C: Surveillance, Case Definition, and Investigation Hepatitis C: Surveillance, Case Definition, and Investigation Tuesday, November 14, 2017 10am 11:30am NJ Department of Health Communicable Disease Service Welcome to the Webinar Today s webinar is being

More information

Technical guidance for Round 9 Global Fund HIV proposals

Technical guidance for Round 9 Global Fund HIV proposals Technical guidance for Round 9 Global Fund HIV proposals Broad Area Service Delivery Area TREATMENT Prevention and assessment of HIV drug resistance (HIVDR) This technical brief provides key information

More information

Liver Cancer Causes, Risk Factors, and Prevention

Liver Cancer Causes, Risk Factors, and Prevention Liver Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for liver cancer.

More information

Approach to the Patient with Abnormal Liver Enzymes

Approach to the Patient with Abnormal Liver Enzymes Approach to the Patient with Abnormal Liver Enzymes Donald Gardenier, DNP, FNP-BC Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai New York, NY Conflict of Interest

More information

GI DISEASE WORKSHOP CASE STUDIES

GI DISEASE WORKSHOP CASE STUDIES GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

TRANSCRIPT. Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18

TRANSCRIPT. Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18 Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com.

More information

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid)

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review

More information